People · Operator

Andris Zoltners

Named in public records as an officer, director or promoter · active 2013–2015 · Biotechnology

1
Companies
6
Filings
$614.0M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Adaptive Biotechnologies CorpBiotechnologySeries D+$614.0M$8.0B2013
Operator network

Andris Zoltners at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Chad Robins · 5 companies · 1 sharedChad RobinsLee Huntsman · 5 companies · 1 sharedLee HuntsmanArnold Levine · 4 companies · 1 sharedArnold LevinePeter Neupert · 4 companies · 1 sharedPeter NeupertJohn Stuelpnagel · 3 companies · 1 sharedJohn StuelpnagelChad Cohen · 2 companies · 1 sharedChad CohenChris Carlson · 2 companies · 1 sharedChris CarlsonCraig Weissman · 2 companies · 1 sharedCraig WeissmanHarlan Robins · 2 companies · 1 sharedHarlan RobinsTom Willis · 2 companies · 1 sharedTom WillisAndy Zoltners · 1 companies · 1 sharedAndy ZoltnersDean Schorno · 1 companies · 1 sharedDean SchornoKathleen Determann · 1 companies · 1 sharedKathleen DetermannRob Hershberg · 1 companies · 1 sharedRob HershbergRob Rosen · 1 companies · 1 sharedRob RosenAdaptive Biotechnologies Corp · $614.0M raisedAdaptive Biotechnolog…Andris ZoltnersAZ
Andris Zoltners Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Andris Zoltners on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Lee Huntsman15
Chad Robins15
Arnold Levine14
Peter Neupert14
John Stuelpnagel13
Chad Cohen12
Harlan Robins12
Chris Carlson12
Tom Willis12
Craig Weissman12
Rob Hershberg11
Andy Zoltners11
Dean Schorno11
Rob Rosen11
Kathleen Determann11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.